Harmine Hydrochloride Capsules for Diabetes

Phase 1

Waitlist Available

Led By James Murrough, MD, PhD

Research Sponsored by James Murrough

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up end of study, at 18 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing harmine to find out how much can be safely given to people. Healthy volunteers will receive one amount of harmine, and researchers will check for any side effects. The information will help decide the next amount for the next person.

Eligible Conditions

Diabetes

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ end of study, at 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~end of study, at 18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and end of study, at 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Dose Limiting Toxicity (DLT)

Secondary study objectives

Visual Analog Scale (VAS)

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Harmine DoseExperimental Treatment1 Intervention

There will be a total of seven possible doses that include 100 mg, 200 mg, 300 mg, 500 mg, 700 mg, 900 mg and 1200 mg. Each study subject will receive a single oral dose of harmine in this single ascending dose design.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Harmine Hydrochloride Capsules

2022

Completed Phase 1

~30

Do I qualify?Apply below to find out